logo

Stock Screener

Forex Screener

Crypto Screener

ALBT

Avalon GloboCare Corp. (ALBT)

$

3.7

+0.03 (0.81%)


Key metrics

Financial statements

Free cash flow per share

Free cash flow per share

-3.6042

Market cap

Market cap

7.2 Million

Price to sales ratio

Price to sales ratio

7.0270

Debt to equity

Debt to equity

-0.0306

Current ratio

Current ratio

0.1934

Income quality

Income quality

0.6493

Average inventory

Average inventory

46.1 Thousand

ROE

ROE

-2.7684



Technology

Technology

Technology – consumer electronics

Largecap

Largecap

With a market cap of 121,78 bil stock is ranked 1

Low risk

Low risk

ISS score of this stock is ranked 1


Company description

Profile

Avalon GloboCare Corp., along with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company provides a range of medical consulting services, which encompass research studies, executive education, daily online executive briefings, and tailored expert advisory services in immunotherapy, as well as second opinion and referral services. Its leading therapeutic candidates include AVA-001, an anti-CD19 CAR-T therapy that has successfully completed first-in-human clinical trials for relapsed/refractory B-cell lymphoblastic leukemia, and AVA-011, which has completed pre-clinical laboratory studies and is currently in the IND-enabling development phase to produce cGMP-grade AVA-011 CAR-T cells. Additionally, Avalon is advancing its RNA-based FASH-CARTM cell therapy platform and developing avalon clinical-grade tissue-specific exosomes (ACTEX). Collaborative efforts with the Massachusetts Institute of Technology (MIT) are directed toward therapeutic and diagnostic targets utilizing QTY-code protein design technology, including creating a hemofiltration device aimed at treating Cytokine Storms. The company also partners with Arbele Limited to co-develop next-generation, transposon-based CAR-T, CAR-NK, and other immune effector cell therapeutic modalities. Notably, a strategic partnership with the University of Natural Resources and Life Sciences in Vienna, Austria, focuses on developing an S-layer vaccine for intranasal or oral administration against SARS-CoV-2 and the coronavirus responsible for COVID-19. Furthermore, Avalon is expanding its Avalon Cell and Avalon Rehab divisions, all while promoting standardization in the exosome industry. The weighted average number of shares outstanding is 936,614.00 highlighting the company's shareholder base. The gross profit stands at $267,829.00 highlighting the company's profitability from core operations. The financial data pertains to the fiscal year 2024. The diluted EPS is -$8.44 accounting for potential share dilution. The company recorded an operating income of -$4,927,732.00 reflecting its earnings from core operations. At present, the stock is affordable at $3.70 making it suitable for budget-conscious investors. Its high average trading volume of 67,795.00 indicates strong liquidity in the market. With a market capitalization of $7,007,689.00 the company is classified as a small-cap player within the industry. Avalon is a key player in the Real Estate - Services industry, significantly contributing to the overall market landscape and driving innovation and growth within the Real Estate sector.

What is Avalon GloboCare Corp. (ALBT)'s current stock price?

The current stock price of Avalon GloboCare Corp. (ALBT) is $3.70 as of 2025-05-29. Prices may fluctuate during the trading day. For real-time updates, check your brokerage platform or financial news websites.

Investing in Avalon GloboCare Corp. (ALBT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.

Analysts predict Avalon GloboCare Corp. stock to fluctuate between $2.11 (low) and $21.60 (high) in the next 365 days, reflecting market expectations and potential volatility.

As of 2025-05-29, Avalon GloboCare Corp.'s market cap is $7,007,689, based on 1,893,970 outstanding shares.

Compared to Meta Platforms, Inc. Class A Common Stock, Avalon GloboCare Corp. has a Lower Market-Cap, indicating a difference in performance.

To buy Avalon GloboCare Corp. (ALBT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALBT. Place an order (Market, Limit, etc.).

The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.

Avalon GloboCare Corp.'s last stock split was 1:15 on 2024-10-28.

Revenue: $1,333,403 | EPS: -$8.44 | Growth: 430.82%.

Visit https://www.avalon-globocare.com/investor-relations for detailed financial reports.

You can explore historical data from here

All-time high: $90.78 (2023-01-03) | All-time low: $2.11 (2024-11-04).

Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.


News

ALBT

prnewswire.com

3 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JWN and ALBT on Behalf of Shareholders

NEW YORK , March 12, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Nordstrom, Inc. (NYSE: JWN)'s  sale to Erik, Pete, Jamie Nordstrom and other members of the Nordstrom family and El Puerto de Liverpool, S.A.B. de C.V. for $24.25 in cash per share.

ALBT

businesswire.com

3 months ago

ALBT Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Avalon GloboCare Corp. is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Avalon GloboCare Corp. (NASDAQ: ALBT) and YOOV Group Holding Limited is fair to Avalon shareholders. Upon closing of the proposed transaction, Avalon shareholders are expected to own between approximately 2.5% to 2.2% of the common stock of the combined company. Halper Sadeh encourages Avalon shareholders to click here to learn more about their legal rights and options or contact Dan.

ALBT

prnewswire.com

3 months ago

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Avalon GloboCare Corp. - ALBT

NEW YORK , March 10, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Avalon GloboCare Corp. (NASDAQ: ALBT ), relating to the proposed merger with YOOV Group Holding Limited.

ALBT

businesswire.com

3 months ago

Shareholder Alert: The Ademi Firm investigates whether Avalon GloboCare Corp. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Avalon (Nasdaq: ALBT) for possible breaches of fiduciary duty and other violations of law in its transaction with YOOV. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the reverse merger transaction, Avalon stockholders are expected to collectively own between approximately 2.5% to 2.2% and YOOV.

ALBT

globenewswire.com

6 months ago

Avalon GloboCare Launches “BrAce for Impact" Affiliate Marketing Program for the KetoAir Breathalyzer Device

FREEHOLD, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, today announced the launch of the "BrAce for Impact" affiliate marketing program for KetoAir™, a handheld breathalyzer device equipped with AI-enabled software and Hot App shareable technology, specifically designed for ketogenic health monitoring.

ALBT

globenewswire.com

7 months ago

Avalon GloboCare and Qi Diagnostics Enter into Memorandum of Understanding for Proposed Co-Development of Real-Time Cannabis Breathalyzer for Detecting Potential Impaired Driving

FREEHOLD, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, today announced that it entered into a memorandum of understanding (the “MOU”) with Qi Diagnostics Limited (“Qi Diagnostics”), a nanosensor-based diagnostic technologies company, to explore a proposed strategic collaboration to co-develop a VOC (volatile organic compound) nanosensor-based point-of-care cannabis breathalyzer. The MOU provides Avalon with an exclusivity period of 120 days (the “Exclusivity Period”), during which Avalon intends to negotiate with Qi Diagnostics and enter into a definitive agreement regarding the proposed strategic collaboration.

ALBT

investorplace.com

10 months ago

Why Is Avalon GloboCare (ALBT) Stock Up 173% Today?

Avalon GloboCare (NASDAQ: ALBT ) stock is up on Wednesday alongside news of a new medical device being launched by Laboratory Services MSO. Laboratory Services MSO is preparing to launch its GeeWhiz External Condom Catheter in the third quarter of 2024.

ALBT

globenewswire.com

10 months ago

Avalon's Laboratory Services MSO Launches DNA Testing Kit for Predisposition to Opioid Addiction

Direct-To-Consumer, Non-Invasive Kit is Available in the U.S. for Convenient At-Home Sample Collection Direct-To-Consumer, Non-Invasive Kit is Available in the U.S. for Convenient At-Home Sample Collection

ALBT

proactiveinvestors.com

a year ago

Avalon GloboCare unveils KetoAir breathalyzer at KetoCon 2024

Avalon GloboCare Corp (NASDAQ:ALBT) said it had successfully launched its KetoAir breathalyzer in the US at the Hack Your Health by KetoCon 2024 Conference. Avalon CEO David Jin told shareholders that the booth at the event in Austin “attracted a diverse group of potential clients and partners, including doctors, disease management companies, health and keto coaches, consumers, keto product manufacturers, and service providers interested in establishing a marketplace on our app and device.

ALBT

investorplace.com

a year ago

Why Is Avalon Globocare (ALBT) Stock Down 27% Today?

Avalon Globocare (NASDAQ: ALBT ) stock is down on Tuesday but only after the commercial real estate company's shares underwent a massive rally on Monday on a recent filing. That rally came after the company filed its Form 10-Q with the Securities and Exchange Commission (SEC).

See all news

logo
Stocks, Indicators, Pattern screeners all at one place
Stock Screener
Forex Screener
Crypto Screener